{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:12:00Z","timestamp":1751436720404},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11894-010-0124-1","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T00:23:37Z","timestamp":1281313417000},"page":"408-416","source":"Crossref","is-referenced-by-count":21,"title":["Emerging Pharmacologic Therapies for Irritable Bowel Syndrome"],"prefix":"10.1007","volume":"12","author":[{"given":"Noriaki","family":"Manabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banny S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"124_CR1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bjp.0705741","volume":"141","author":"M Camilleri","year":"2004","unstructured":"Camilleri M: Treating irritable bowel syndrome: overview, perspective and future therapies. Br J Pharmacol 2004, 141:1237\u20131248.","journal-title":"Br J Pharmacol"},{"key":"124_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","volume":"132","author":"MD Gershon","year":"2007","unstructured":"Gershon MD, Tack J: The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397\u2013414.","journal-title":"Gastroenterology"},{"key":"124_CR3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.dld.2009.07.009","volume":"41","author":"M Camilleri","year":"2009","unstructured":"Camilleri M, Andresen V: Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009, 41:854\u2013862.","journal-title":"Dig Liver Dis"},{"key":"124_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2009.04153.x","volume":"31","author":"M Camilleri","year":"2010","unstructured":"Camilleri M: Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther 2010, 31:35\u201346.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR5","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","volume":"358","author":"M Camilleri","year":"2008","unstructured":"\u2022\u2022 Camilleri M, Kerstens R, Rykx A, et al.: A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008, 358:2344\u20132354. This article describes the first pivotal phase 3 trial demonstrating that about 30% of patients with constipation achieve three or more SCBMs per week on prucalopride, compared to 12% on placebo.","journal-title":"N Engl J Med"},{"key":"124_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","volume":"29","author":"EM Quigley","year":"2009","unstructured":"\u2022\u2022 Quigley EM, Vandeplassche L, Kerstens R, et al.: Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009, 29:315\u2013328. This article describes one of the three pivotal phase 3 trials reporting on the efficacy and tolerability of prucalopride in patients with severe constipation.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","volume":"58","author":"J Tack","year":"2009","unstructured":"\u2022\u2022 Tack J, van Outryve M, Beyens G, et al.: Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009, 58:357\u2013365. This article describes one of the three pivotal phase 3 trials showing that prucalopride improves bowel function, associated symptoms, and satisfaction in chronically constipated patients.","journal-title":"Gut"},{"key":"124_CR8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/gast.2001.21166","volume":"120","author":"EP Bouras","year":"2001","unstructured":"Bouras EP, Camilleri M, Burton DD, et al.: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001, 120:354\u2013360.","journal-title":"Gastroenterology"},{"key":"124_CR9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2036.2002.01210.x","volume":"16","author":"CE Sloots","year":"2002","unstructured":"Sloots CE, Poen AC, Kerstens R, et al.: Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002, 16:759\u2013767.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.2002.01272.x","volume":"16","author":"AV Emmanuel","year":"2002","unstructured":"Emmanuel AV, Roy AJ, Nicholls TJ, et al.: Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002, 16:1347\u20131356.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000070202","volume":"67","author":"G Coremans","year":"2003","unstructured":"Coremans G, Kerstens R, De Pauw M, et al.: Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003, 67:82\u201389.","journal-title":"Digestion"},{"key":"124_CR12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2982.2006.00865.x","volume":"19","author":"M Camilleri","year":"2007","unstructured":"\u2022\u2022 Camilleri M, Vazquez-Roque MI, Burton D, et al.: Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007, 19:30\u201338. This phase 2 trial demonstrated that ATI-7505 accelerates overall colonic transit, and tends to accelerate gastric emptying and loosen stool consistency in healthy subjects.","journal-title":"Neurogastroenterol Motil"},{"key":"124_CR13","doi-asserted-by":"crossref","first-page":"A641","DOI":"10.1053\/j.gastro.2004.01.030","volume":"126","author":"D Dennis","year":"2004","unstructured":"Dennis D, Palme M, Irwin I, et al.: ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dog. Gastroenterology 2004, 126:A641","journal-title":"Gastroenterology"},{"key":"124_CR14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2982.2009.01378.x","volume":"22","author":"ML Manini","year":"2010","unstructured":"\u2022\u2022 Manini ML, Camilleri M, Goldberg M, et al.: Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010, 22:42\u201349. This phase 2 trial demonstrated that velusetrag (TD-5108) accelerates intestinal and colonic transit after single dosing and accelerates gastric emptying after multiple dosing in healthy subjects and patients with constipation.","journal-title":"Neurogastroenterol Motil"},{"key":"124_CR15","first-page":"A545","volume":"134","author":"MR Goldberg","year":"2008","unstructured":"Goldberg MR, Li YP, Pitzer K, et al.: TD-5108, a selective 5-HT 4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008, 134:A545.","journal-title":"Gastroenterology"},{"key":"124_CR16","first-page":"A60","volume":"132","author":"MR Goldberg","year":"2007","unstructured":"Goldberg MR, Wong SL, Ganju J, et al.: TD-5108, a selective 5-HT 4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology 2007, 132:A60.","journal-title":"Gastroenterology"},{"key":"124_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10787-006-1537-1","volume":"15","author":"T Hirata","year":"2007","unstructured":"Hirata T, Funatsu T, Keto Y, et al.: Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacol 2007, 15:5\u20139.","journal-title":"Inflammopharmacol"},{"key":"124_CR18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2982.2007.01069.x","volume":"20","author":"T Hirata","year":"2008","unstructured":"Hirata T, Keto Y, Nakata M, et al.: Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 2008, 20:557\u2013565.","journal-title":"Neurogastroenterol Motil"},{"key":"124_CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000150632","volume":"77","author":"K Matsueda","year":"2008","unstructured":"Matsueda K, Harasawa S, Hongo M, et al.: A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008, 77:225\u2013235.","journal-title":"Digestion"},{"key":"124_CR20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/00365520802240255","volume":"43","author":"K Matsueda","year":"2008","unstructured":"\u2022 Matsueda K, Harasawa S, Hongo M, et al.: A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008, 43:1202\u20131211. This phase 3 trial demonstrated that ramosetron hydrochloride is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habit in patients with diarrhea-predominant irritable bowel syndrome.","journal-title":"Scand J Gastroenterol"},{"key":"124_CR21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000185719","volume":"78","author":"AW Mangel","year":"2008","unstructured":"Mangel AW, Chaturvedi P: Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008, 78:180\u2013186.","journal-title":"Digestion"},{"key":"124_CR22","first-page":"625","volume":"17","author":"R Ueno","year":"2005","unstructured":"Ueno R, Engelke KJ, Osama H: Effect of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Neurogastroenterol Motil 2005, 17:625.","journal-title":"Neurogastroenterol Motil"},{"key":"124_CR23","doi-asserted-by":"crossref","first-page":"G647","DOI":"10.1152\/ajpgi.00183.2006","volume":"292","author":"AJ Moeser","year":"2007","unstructured":"Moeser AJ, Nighot PK, Engelke KJ, et al.: Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007, 292:G647\u2013G656.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"124_CR24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1152\/ajpgi.00264.2005","volume":"290","author":"M Camilleri","year":"2006","unstructured":"Camilleri M, Bharucha AE, Ueno R, et al.: Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006, 290:942\u2013947.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"124_CR25","doi-asserted-by":"crossref","first-page":"G295","DOI":"10.1152\/ajpgi.90558.2008","volume":"296","author":"S Sweetser","year":"2009","unstructured":"Sweetser S, Busciglio IA, Camilleri M, et al.: Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor function in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009, 296:G295\u2013G301.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"124_CR26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","volume":"27","author":"JF Johanson","year":"2008","unstructured":"Johanson JF, Drossman DA, Panas R, et al.: Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008, 27:685\u2013696.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","volume":"133","author":"V Andersen","year":"2007","unstructured":"\u2022\u2022 Andersen V, Camilleri M, Busciglio IA, et al.: Effect of 5\u00a0days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007, 133:761\u2013768. This phase 2a trial showed that linaclotide, 1000\u00a0\u03bcg once daily, significantly accelerated ascending colonic transit and altered bowel function.","journal-title":"Gastroenterology"},{"key":"124_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ajg.2008.59","volume":"104","author":"JM Johnston","year":"2009","unstructured":"Johnston JM, Kurtz CB, Drossman DA, et al.: Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009, 104:125\u2013132.","journal-title":"Am J Gastroenterol"},{"key":"124_CR29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","volume":"138","author":"AJ Lembo","year":"2010","unstructured":"\u2022\u2022 Lembo AJ, Kurtz CB, Macdougall JE, et al.: Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010, 138:886\u2013895.e1. This article reports a phase 2b trial of efficacy of linaclotide therapy with few adverse events in patients with chronic constipation.","journal-title":"Gastroenterology"},{"key":"124_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cgh.2009.10.020","volume":"8","author":"ST Odunsi-Shiyanbade","year":"2010","unstructured":"\u2022\u2022 Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al.: Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010, 8:159\u2013165. Two randomized, double-blind, placebo-controlled studies showed that sodium chenodeoxycholate in health and colesevelam in diarrhea-predominant irritable bowel syndrome have opposite effects on colonic transit and fecal parameters.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"124_CR31","first-page":"S224","volume":"138","author":"A Rao","year":"2010","unstructured":"Rao A, Odunsi ST, Camilleri M, et al.: Dose-related effects of chenodeoxycholate on gastrointestinal and colonic transit and bowel function in female patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2010, 138:S224.","journal-title":"Gastroenterology"},{"key":"124_CR32","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1572-0241.2007.01438.x","volume":"102","author":"F Fern\u00e1ndez-Ba\u00f1ares","year":"2007","unstructured":"\u2022 Fern\u00e1ndez-Ba\u00f1ares F, Esteve M, Salas A, et al.: Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007, 102:2520\u20132528. This prospective study assessed the presence of gluten-sensitive enteropathy, bile acid malabsorption, and sugar malabsorption in consecutive patients with chronic watery diarrhea of obscure origin fulfilling Rome II criteria.","journal-title":"Am J Gastroenterol"},{"key":"124_CR33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2982.2009.01288.x","volume":"21","author":"M Camilleri","year":"2009","unstructured":"Camilleri M, Nadeau A, Tremaine WJ, et al.: Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009, 21:734\u2013739.","journal-title":"Neurogastroenterol Motil"},{"key":"124_CR34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1572-0241.2003.07542.x","volume":"98","author":"SP Dunlop","year":"2003","unstructured":"Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98:1578\u20131583.","journal-title":"Am J Gastroenterol"},{"key":"124_CR35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","volume":"128","author":"L O\u2019Mahony","year":"2005","unstructured":"O\u2019Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541\u2013551.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"124_CR36","first-page":"156","volume":"136","author":"B Lobo","year":"2009","unstructured":"Lobo B, Vicario M, Martinez C, et al.: Clinical benefit in IBS after disodium cromoglycate involves mast cell-medicated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa. Gastroenterology 2009, 136(Suppl 1):156.","journal-title":"Gastroenterology"},{"key":"124_CR37","unstructured":"Klooker TK, Koopman KE, Heide S, et al.: Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Proceedings of the United European Gastroenterology Federation (UEGF) Meeting. Vienna, Austria; 2008:OP397."},{"key":"124_CR38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2036.2009.04041.x","volume":"30","author":"R Corinaldesi","year":"2009","unstructured":"Corinaldesi R, Stanghellini V, Cremon C, et al.: Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009, 30:245\u2013252.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.2003.01640.x","volume":"18","author":"SP Dunlop","year":"2003","unstructured":"Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77\u201384.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0016-5085(99)70226-X","volume":"116","author":"M Delvaux","year":"1999","unstructured":"Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116:38\u201345.","journal-title":"Gastroenterology"},{"key":"124_CR41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1152\/ajpgi.00360.2002","volume":"284","author":"S Delgado-Aros","year":"2003","unstructured":"Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a \u03ba-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003, 284:558\u2013566.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"124_CR42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.2008.03730.x","volume":"28","author":"AW Mangel","year":"2008","unstructured":"Mangel AW, Bornstein JD, Hamm LR, et al.: Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008, 28:239\u2013249.","journal-title":"Aliment Pharmacol Ther"},{"key":"124_CR43","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.cgh.2007.07.011","volume":"5","author":"LA Szarka","year":"2007","unstructured":"\u2022 Szarka LA, Camilleri M, Burton D, et al.: Efficacy of on-demand asimadoline, a peripheral \u03ba-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007, 5:1268\u20131275. This randomized study compared the effect of the \u03ba-opioid agonist, asimadoline, and placebo on episodes of abdominal pain in patients with IBS.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"124_CR44","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1053\/gast.1997.v112.agast972120","volume":"112","author":"J Kanto","year":"1997","unstructured":"Kanto J, Kangas L, Leppanen T, et al.: Tofizopam: a technical review for practice guideline development. Gastroenterology 1997, 112:2120\u20132137.","journal-title":"Gastroenterology"},{"key":"124_CR45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2036.2007.03566.x","volume":"27","author":"SM Leventer","year":"2008","unstructured":"Leventer SM, Raudibaugh K, Frissora CL, et al.: Clinical trial: dextofisopam in the treatment of patients with diarrhea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008, 27:197\u2013206.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-010-0124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-010-0124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-010-0124-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T06:06:38Z","timestamp":1711692398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-010-0124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s11894-010-0124-1","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}